
Arcturus Therapeutics is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 177 staff and has a trailing 12-month revenue of around $51.5 million.
How to buy Arcturus Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ARCT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Arcturus Therapeutics stock price (NASDAQ: ARCT)
Use our graph to track the performance of ARCT stocks over time.Arcturus Therapeutics shares at a glance
Latest market close | $21.24 |
---|---|
52-week range | $11.70 - $31.41 |
50-day moving average | $17.97 |
200-day moving average | $17.54 |
Wall St. target price | $43.75 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-7.53 |
Buy Arcturus Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Arcturus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arcturus Therapeutics price performance over time
Historical closes compared with the close of $21.24 from 2023-02-06
1 week (2023-01-31) | 0.52% |
---|---|
1 month (2023-01-06) | 29.43% |
3 months (2022-11-08) | -6.92% |
6 months (2022-08-08) | 1.05% |
1 year (2022-02-08) | -15.31% |
---|---|
2 years (2021-02-08) | -75.56% |
3 years (2020-02-07) | 76.56% |
5 years (2018-02-07) | 231.88% |
Arcturus Therapeutics financials
Revenue TTM | $51.5 million |
---|---|
Gross profit TTM | $12.4 million |
Return on assets TTM | -25.22% |
Return on equity TTM | -72.46% |
Profit margin | -284.78% |
Book value | $5.50 |
Market capitalisation | $585.3 million |
TTM: trailing 12 months
Arcturus Therapeutics share dividends
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Have Arcturus Therapeutics's shares ever split?
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Arcturus Therapeutics share price volatility
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $11.7 up to $31.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.5563. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics overview
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U. S.
Arcturus Therapeutics in the news
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Frequently asked questions
What percentage of Arcturus Therapeutics is owned by insiders or institutions?Currently 13.861% of Arcturus Therapeutics shares are held by insiders and 79.295% by institutions. How many people work for Arcturus Therapeutics?
Latest data suggests 177 work at Arcturus Therapeutics. When does the fiscal year end for Arcturus Therapeutics?
Arcturus Therapeutics's fiscal year ends in December. Where is Arcturus Therapeutics based?
Arcturus Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121 What is Arcturus Therapeutics's ISIN number?
Arcturus Therapeutics's international securities identification number is: US03969T1097 What is Arcturus Therapeutics's CUSIP number?
Arcturus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03969T109
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert